Chemcon Speciality Chemicals files Rs 350 crore IPO papers with SEBI Medical Dialogues Bureau10 Aug 2019 9:30 AM ISTThe key customers of the company's pharmaceutical chemicals include Hetero Labs, Laurus Labs, Aurobindo Pharma and IndSwift Laboratories. The shares...
Amgen wins patent battle against Novartis for blockbuster arthritis drug Enbrel Medical Dialogues Bureau10 Aug 2019 9:20 AM ISTEnbrel generated $5.01 billion in sales for Amgen in 2018 and belongs to a class of medications known as biologics, made from living cells and are...
Patient groups push back against Gilead pricey HIV prevention treatment Descovy Medical Dialogues Bureau10 Aug 2019 9:15 AM ISTSuch groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. But at least three U.S. organizations now...
Alembic Pharma gets tentative USFDA nod for Bimatoprost Ophthalmic Solution Medical Dialogues Bureau9 Aug 2019 10:00 AM ISTAlembic Pharma's Bimatoprost Ophthalmic Solution is therapeutically equivalent to the reference listed drug product Lumigan ophthalmic solution 0.01...
Meril Life Sciences gets European Conformity mark for Bioresorbable Scaffold MeRes100 Medical Dialogues Bureau9 Aug 2019 9:45 AM ISTMeril Life Sciences MeRes100 has received both Drug Controller General of India(DCGI) and CE (European Conformity) marketing approval. New Delhi:...
Lupin net profit rises 49.46 percent to Rs 303 crore for June quarter Medical Dialogues Bureau9 Aug 2019 9:30 AM ISTConsolidated sales for the quarter under review also rose to Rs 4,355.83 crore as against Rs 3,774.57 crore during the same period a year ago, Lupin...
Knew about Zolgensma data problems before US approval: Novartis Medical Dialogues Bureau9 Aug 2019 9:15 AM IST"We made the decision to progress our quality investigation prior to informing FDA and other regulatory authorities so that we could provide the best...
Bayer buys BlueRock in USD 600 million bet on stem cell therapies Medical Dialogues Bureau9 Aug 2019 9:00 AM ISTFRANKFURT: German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up...
Cadila Healthcare gets OAI letter from USFDA for Moraiya facility Medical Dialogues Bureau8 Aug 2019 10:00 AM ISTThe company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
Aurobindo Pharma Q1 net profit up by 39.52 percent to Rs 636 crore Farhat Nasim8 Aug 2019 9:45 AM IST"We have started the year with a healthy performance. Enhancing our quality management practices and adhering to the regulatory requirements continues...
GSK ends Ebola vaccine RnD; transfers license to US institute Medical Dialogues Bureau8 Aug 2019 9:30 AM ISTGSK had put its Ebola vaccine work on hold after it was unable to progress the product through the final stage, or Phase III, clinical trials toward...
Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA Medical Dialogues Bureau8 Aug 2019 9:15 AM ISTThe FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval of...
